Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

Author： Acharya Milin   Karp Judith   Sausville Edward   Hwang Kyunghwa   Ryan Qin   Gojo Ivana   Venitz Jűrgen   Figg William   Sparreboom Alex  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.5, 2006-09, pp. : 367-375

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Romidepsin: a novel histone deacetylase inhibitor for cancer

By Bertino Erin M   Otterson Gregory A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1151-1158

Informa Healthcare

Access to resources Recommend Favorite

The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases

By  

Current Cancer Drug Targets, Vol. 13, Iss. 4, 2013-05 ,pp. : 411-422

Bentham Science Publishers

Access to resources Recommend Favorite

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

By Oh Eun-Taex  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 435-442

Springer Publishing Company

Access to resources Recommend Favorite

Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

By  

Drug Metabolism Letters, Vol. 1, Iss. 2, 2007-04 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl- XL

By Hwang Jung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1434-1442

Springer Publishing Company

Access to resources Recommend Favorite